US 9556277
Method of treating a TL1A-associated disease or disorder with human antibodies to TL1A
granted A61KA61K2039/505A61K39/3955
Quick answer
US patent 9556277 (Method of treating a TL1A-associated disease or disorder with human antibodies to TL1A) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K39/39558, A61K45/06